Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

0.6502
+0.00030.05%
Volume:215.66K
Turnover:141.60K
Market Cap:12.66M
PE:-0.07
High:0.6720
Open:0.6400
Low:0.6400
Close:0.6499
52wk High:15.75
52wk Low:0.1614
Shares:19.48M
Float Shares:17.03M
Volume Ratio:0.31
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.5973
EPS(LYR):-28.4188
ROE:-1371.64%
ROA:-84.57%
PB:1.09
PE(LYR):-0.02

Loading ...

Moleculin Biotech Q1 EPS USD -3.54

THOMSON REUTERS
·
May 15

Moleculin reports 40% blinded remission rate in pivotal MIRACLE AML trial

Reuters
·
May 15

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal Miracle Trial

THOMSON REUTERS
·
May 15

Moleculin Biotech Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

Moleculin Biotech Q1 FY26 net loss widens to $12.85 million; operating loss widens to $7.87 million

Reuters
·
May 15

Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target

TIPRANKS
·
May 15

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding

Benzinga
·
May 14

Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

TIPRANKS
·
May 13

BRIEF-Moleculin Biotech Inc - To Unblind Miracle Trial Data Before June 30, 2026 - SEC Filing

Reuters
·
May 13

Moleculin Biotech Inc - Miracle Trial on Track to Complete Part a Recruitment in Q3 2026 - SEC Filing

THOMSON REUTERS
·
May 13

Moleculin nears MIRACLE trial unblinding for Annamycin in relapsed AML by June 30

Reuters
·
May 13

Moleculin announces publication on cardiac safety profiloe of annamycin

TIPRANKS
·
May 13

Moleculin says Cleveland Clinic review finds no significant Annamycin cardiotoxicity in R/R AML

Reuters
·
May 12

Moleculin Biotech issued liposomal Annamycin patent in Hong Kong

TIPRANKS
·
May 08

Moleculin Biotech secures Hong Kong patent for liposomal Annamycin reconstitution method

Reuters
·
May 08

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

GlobeNewswire
·
May 08

Moleculin says Annamycin extends survival 60% in pancreatic cancer preclinical models

Reuters
·
Apr 23

Moleculin to present annamycin cardiac safety pooled analysis at ASCO 2026

Reuters
·
Apr 21

Moleculin Biotech Stockholders Approve Warrant Share Issuance

TIPRANKS
·
Apr 15

Moleculin CEO highlights Annamycin’s non-cardiotoxic profile in CEO Corner interview

Reuters
·
Apr 08